Universal DX Presents Data at EACR Virtual Congress; Top-scoring Poster Shows Accurate Detection of Colorectal Advanced Adenomas

New results from the OMICS study, the company`s prospective, international, multi-center study, show Universal DX`s blood test can detect colorectal advanced adenomas at 55% sensitivity and 90% specificity, which exceeds currently available non-invasive tests for colorectal cancer screening

80% of sporadic colorectal cancers arise from pre-malignant advanced adenomas, making early detection critical to saving lives

(JUNE 9, 2021) CAMBRIDGE, MA. - Universal Diagnostics (UDX), a bioinformatics and multi-omics company on a mission to transform cancer into a curable disease, today announced at the European Association of Cancer Research (EACR) 2021 virtual conference the results of an international multicenter observational cohort study: The detection of colorectal advanced adenomas (AAs) with 55% sensitivity and 90% specificity using single targeted sequencing analysis of methylation markers, advanced computational biology and machine learning algorithms.

Last week, the company presented similarly promising data at the 2021 ASCO Annual Meeting: CRC detection at 92% sensitivity and 97% specificity.

Setting Universal DX apart in the exciting and growing liquid biopsy market is its focus on identifying cancer in its earliest, even pre-cancerous, stages. When compared to currently available and FDA-approved blood and stool-based tests, Universal DX`s blood test demonstrated significantly higher accuracy for detecting advanced adenomas.

"We have demonstrated that we can identify cancer in its earliest stages with 90+% sensitivity, which is a critical first step to transforming cancer into a curable disease" said Christian Hense, managing director at Universal DX. "But where we really want to get to is to prevent colorectal cancer all together. With the findings presented at EACR, we are on the path to a minimally-invasive blood test that can identify cancer in its pre-cancerous forms, enabling us to prevent what is currently the 3rd most common type of cancer in men and 2nd in women worldwide. This test will reduce incidence of colorectal cancer."